Executive Chairman Sapirstein resigns; Interim CFO Fedasz appointed Interim CEO

Onconetix, Inc.

James Sapirstein resigned as Executive Chairman and Board member, effective March 28, 2025.
Karina Fedasz, 52, previously Interim CFO, appointed Interim CEO effective April 2, 2025.
Fedasz has background in finance, M&A, and capital raising; formerly CFO at IDW Media Holdings and Head of Business Development at Evofem Biosciences.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Karina Fedasz

Interim Chief Executive Officer

ONCO · Onconetix, Inc.

Effective: 2025-04-02
Filed: April 3, 2025, 7:59 PM ET

On April 2, 2025, the Company appointed Karina Fedasz, 52, the Company’s Interim Chief Financial Officer, as Interim Chief Executive Officer of the Company, effective immediately.

Departed

James Sapirstein

Executive Chairman

ONCO · Onconetix, Inc.

Effective: 2025-03-28
Filed: April 3, 2025, 7:59 PM ET

Effective as of March 28, 2025, James Sapirstein resigned as Executive Chairman and a member of the Board of Directors (the “Board”) of Onconetix, Inc. (the “Company”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Karina Fedasz was appointed as Interim Chief Executive Officer at Onconetix, Inc..

Action: appointed
Role: Interim Chief Executive Officer

Exact text from the filing

On April 2, 2025, the Company appointed Karina Fedasz, 52, the Company’s Interim Chief Financial Officer, as Interim Chief Executive Officer of the Company, effective immediately.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

James Sapirstein resigned as Executive Chairman at Onconetix, Inc..

Action: resigned
Role: Executive Chairman

Exact text from the filing

Effective as of March 28, 2025, James Sapirstein resigned as Executive Chairman and a member of the Board of Directors (the “Board”) of Onconetix, Inc. (the “Company”).

View on SEC.gov

Onconetix, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-25-028646

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.